Subban Vijayakumar, Lakshmanan Anitha, Victor Suma M, Pakshirajan Balaji, Udayakumaran Kalaichelvan, Gnanaraj Anand, Solirajaram Ramkumar, Krishnamoorthy Jaishankar, Janakiraman Ezhilan, Pandurangi Ulhas M, Kalidoss Latchumanadhas, Mullasari Ajit Sankardas
Consultant, Department of Cardiology, Institute of Cardio-Vascular Diseases, Madras Medical Mission, Chennai, India.
Physician Assistant, Department of Cardiology, Institute of Cardio-Vascular Diseases, Madras Medical Mission, Chennai, India.
Indian Heart J. 2014 Jan-Feb;66(1):25-30. doi: 10.1016/j.ihj.2013.12.036. Epub 2014 Jan 3.
To assess the feasibility and outcomes of primary percutaneous coronary intervention (PPCI) for ST-segment elevation myocardial infarction (STEMI) in Indian Scenario.
Between January 2005 and December 2012, consecutive STEMI patients who underwent PPCI within 12 h of onset of chest pain were prospectively enrolled in a PPCI registry. Patient demographics, risk factors, procedural characteristics, time variables and in-hospital and 30 day major adverse cardiovascular events (MACE) [death, reinfarction, bleeding, urgent coronary artery bypass surgery (CABG) and stroke] were assessed.
A total of 672 patients underwent PPCI during this period. The mean age was 52 ± 13.4 years and 583 (86.7%) were males, 275 (40.9%) were hypertensives and 336 (50%) were diabetics. Thirty one (4.6%) patients had cardiogenic shock (CS). Anterior myocardial infarction was diagnosed in 398 (59.2%) patients. The median chest pain onset to hospital arrival time, door-to-balloon time and total ischemic times were 200 (10-720), 65 (20-300), and 275 (55-785) minutes respectively. In-hospital adverse events occurred in 54 (8.0%) patients [death 28 (4.2%), reinfarction 8 (1.2%), major bleeding 9 (1.3%), urgent CABG 4 (0.6%) and stroke 1 (0.14%)]. Nineteen patients with CS died (mortality rate - (61.3%)). At the end of 30 days, 64 (9.5%) patients had MACE [death 35 (5.2%), reinfarction 10 (2.1%), major bleeding 10 (1.5%), urgent CABG 4 (0.6%) and stroke 1 (0.1%)].
Our study has shown that PPCI is feasible with good outcomes in Indian scenario. Even though the recommended door-to-balloon time can be achieved, the total ischemic time remained long. CS in the setting of STEMI was associated with poor outcomes.
评估在印度情况下,对ST段抬高型心肌梗死(STEMI)患者进行直接经皮冠状动脉介入治疗(PPCI)的可行性及治疗结果。
在2005年1月至2012年12月期间,将胸痛发作12小时内接受PPCI的连续性STEMI患者前瞻性纳入PPCI登记系统。评估患者的人口统计学资料、危险因素、手术特征、时间变量以及住院期间和30天内的主要不良心血管事件(MACE)[死亡、再梗死、出血、紧急冠状动脉旁路移植术(CABG)和中风]。
在此期间,共有672例患者接受了PPCI。平均年龄为52±13.4岁,男性583例(86.7%),高血压患者275例(40.9%),糖尿病患者336例(50%)。31例(4.6%)患者发生心源性休克(CS)。398例(59.2%)患者被诊断为前壁心肌梗死。胸痛发作至入院时间、门球时间和总缺血时间的中位数分别为200(10 - 720)分钟、65(20 - 300)分钟和275(55 - 785)分钟。54例(8.0%)患者发生住院不良事件[死亡28例(4.2%),再梗死8例(1.2%),大出血9例(1.3%),紧急CABG 4例(0.6%),中风1例(0.14%)]。19例CS患者死亡(死亡率 - (61.3%))。在30天结束时,64例(9.5%)患者发生MACE[死亡35例(5.2%),再梗死10例(2.1%),大出血10例(1.5%),紧急CABG 4例(0.6%),中风1例(0.1%)]。
我们的研究表明,在印度情况下,PPCI是可行的,且治疗结果良好。尽管可以达到推荐的门球时间,但总缺血时间仍然较长。STEMI患者发生CS与不良预后相关。